Viromed Medical AG has secured approval in Turkey for its ViroCAP® med medical device, a development that accelerates the company's commercial launch in a strategically important healthcare market and underscores the growing acceptance of cold plasma technology in medical applications. The approval, granted for the MDR Class IIa device, came significantly earlier than anticipated—originally expected in February or March 2027—following the summer registration of ViroCAP® derma with Turkey's National Medical Device Tracking System (ÜTS).
The timing matters because it allows Viromed to begin deliveries against binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028, providing near-term revenue visibility in a market where reimbursement discussions with Turkish health insurers are already underway. For a company focused on expanding the use of cold plasma in medicine, early market access in Turkey serves as a proof point for its international strategy and a foundation for further growth in the region.
ViroCAP® med is designed for professional use by qualified medical personnel and supports the treatment of open wounds as well as intraoperative use of cold atmospheric plasma. The application is contactless and mobile, with each session planned to last one to two minutes while skin temperature remains below 40 degrees Celsius—characteristics that make the technology practical for clinical settings and potentially attractive to healthcare providers seeking efficient wound-care solutions.
Beyond Turkey, Viromed and its partner Umeco have initiated approval processes for ViroCAP® med in additional Asian countries, building on the product's prior EU approval as an MDR Class IIa device, which is a prerequisite for local approvals outside the EU. This parallel expansion signals that the Turkish approval is not an isolated win but part of a broader regulatory and commercial push that could multiply the addressable market for Viromed's cold plasma platform.
In Germany, Viromed has achieved its first reimbursement of ViroCAP® by a statutory health insurer through a selective contract in Lower Saxony, focused on preventing infections at the driveline exit site in patients with a left ventricular assist device (LVAD). The company is in advanced discussions for further selective contracts in three additional German federal states, which, if concluded, would strengthen domestic adoption and validate the health-economic value of the technology. Reimbursement is often the critical bottleneck for medical device adoption, so progress on this front is a key indicator of long-term commercial viability.
Viromed is also advancing its clinical evidence base. A successfully completed retrospective study on the prevention of postoperative wound infections is set to be published in November, and the company is starting a randomized study on ViroCAP® use in LVAD patients as well as a further study in the field of heart valves. These studies could support broader clinical acceptance and pave the way for additional indications, reinforcing the company's position as a pioneer of cold plasma technology. For investors and industry observers, the combination of early regulatory approval, binding orders, reimbursement progress, and expanding clinical research makes Viromed a company to watch in the medical technology space. More information is available via www.newmediawire.com and the company's website at www.viromed-medical-ag.de.


